Moxonidin Viatris (Moxonidine)

• Moxonidine is an antihypertensive agent that acts on central imidazoline I1 receptors to control elevated blood pressure.
• Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension.
• Resistant hypertension: may be added when blood pressure remains uncontrolled despite standard therapy.
• Cardiovascular risk management: contributes to overall risk reduction by lowering sympathetic outflow.

• Moxonidine selectively stimulates central imidazoline I1 receptors in the medulla, which diminishes sympathetic nervous system activity. This reduction in sympathetic outflow leads to decreased peripheral vascular resistance and lower heart rate, resulting in a sustained decline in arterial blood pressure.

Moxonidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dry mouth: sensation of oral dryness.
• Fatigue: feeling of tiredness or lack of energy.
• Dizziness: light‑headed feeling, especially on standing.
• Headache: mild to moderate cranial pain.
• Nausea: upset stomach or urge to vomit.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe hypotension: markedly low blood pressure requiring medical attention.
• Bradycardia: unusually slow heart rate.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Syncope: sudden loss of consciousness.
• Cardiac arrhythmia: irregular heart rhythm.

• Before initiating therapy with Moxonidine, clinicians should evaluate patient‑specific factors and monitor for potential complications.
• Assess renal function: adjust use in patients with severe renal impairment.
• Evaluate hepatic status: caution in moderate to severe liver disease.
• Elderly patients: start at lower dose and monitor for hypotension.
• Pregnancy and lactation: use only if benefit outweighs risk, as safety data are limited.
• Concomitant antihypertensives: monitor blood pressure to avoid excessive lowering.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Moxonidine can interact with other medicines that affect blood pressure or central nervous system activity.

Major Interactions (Avoid)

• Co‑administration with other central antihypertensives (e.g., clonidine) may cause profound hypotension.
• Combined use with potent CYP2D6 inhibitors can increase plasma levels.
• Concurrent imidazoline agonists may amplify sympatholytic effects.

Moderate Interactions (Monitor Closely)

• Diuretics may enhance the hypotensive response.
• ACE inhibitors or ARBs can increase risk of low blood pressure.
• Beta‑blockers may lead to additive bradycardia.
• NSAIDs may attenuate the antihypertensive effect.
• Alcohol can potentiate dizziness and hypotension.